4503 — Astellas Pharma Share News
0.000.00%
Last trade - 00:00Health Rounds: New blood test finds early risk for ovarian cancer
Health Rounds: New blood test finds early risk for ovarian cancer
Refile: Astellas employee imprisoned in China to be released in December, Japanese media report
Table: Astellas Pharma -6-MTH group results (IFRS)
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Astellas Enters Voluntary Agreement With US Government For Affordable Medicine Access
Trump administration announces drug pricing deals with CSL, Astellas and others (updated)
Table: Astellas -Q1 group results (IFRS)
Brief: Astellas - Us FDA Approves Padcev Plus Keytruda As Neoadjuvant And Adjuvant Treatment For Muscle-Invasive Bladder Cancer Regardless Of Cisplatin Eligibility
Brief: FDA Approves Pembrolizumab Combination For Muscle Invasive Bladder Cancer
Focus: Trump's push for the world's lowest drug prices hits snag with mid-sized companies
China detains two Japanese nationals suspected of smuggling banned goods (updated)
Brief: Astellas Pharma: Institutional Shareholder Services Has Issued A Report Recommending A Vote Against A Director Candidate
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Advisory: Alert wrongly tagged to Gold Rain Enterprises withdrawn
Brief: Izervay® (Avacincaptad Pegol Intravitreal Solution) Demonstrated Increased Probability Of Maintaining Driving Eligibility In Geographic Atrophy Patients
Brief: Astellas Pharma Inc - Notice Regarding Impairment Loss And Extraordinary Losses In Non-Consolidated Financial Results(J-GAAP)
Table: Astellas -2025/26 group results (IFRS)